Pfizer files rolling FDA submission for crizotinib to treat ALK-positive lung cancer
This article was originally published in Scrip
Executive Summary
Pfizer has initiated a rolling submission with the US FDA for its oral anaplastic lymphoma kinase (ALK) and cMET inhibitor, crizotinib (PF-02341066), for the treatment of patients with advanced non-small cell lung cancer whose tumours are ALK-positive.